


PVRI 2025 Rio Annual Congress

29 January - 1 February 2025

Embracing Heterogeneity

Windsor Convention & Expo Centre, R. Martinho de Mesquita, 129 - Barra da Tijuca Rio de Janeiro - RJ, 20031-204



Programme overview

Pre-congress satellite meetings, Windsor Oceanico, 2nd Floor, Oceania

Wednesday, 29 January

08:00-16:00	Innovative Drug Development Initiative
08:00-16:00	Infection in Pulmonary Vascular Diseas
08:00-12:00	Paediatric & Congenital Heart Disease
12:30-18:00	PAH-ICON: International Consortium f
13:30-17:15	Imaging Task Force Meeting, Oceania
16:00-18:00	High Altitude Task Force Meeting, Oce
16:00-18:00	PVRI Board Meeting, Oceania VIII

Scientific programme, Windsor Oceanico, 3rd Floor, Asia

Thursday, 30 January: Heterogeneity in the presentation of PH

08:00-11:05	Session 1: Establishing the framework
11:05-13:00	Buffet lunch Windsor Barra, Ground Fl
11:05-13:00	Career Catalyst Luncheon (bookable),
13:00-16:00	Session 2: Risk stratification and treatm
16:00-18:00	Poster presentations
18:00-20:00	Welcome Drinks Reception (open to a

Friday, 31 January: Heterogeneity in the pathobiology of PH

08:00-11:10	Session 3: Vascular heterogeneity in cl
11:10-13:00	Buffet lunch Windsor Barra, Ground Fl
11:10-13:00	Women in PH Luncheon (bookable), W
13:00-16:30	Session 4: Heterogeneity in PH associa
16:30-18:00	Poster presentations
19:00-23:59	Gala Dinner & Awards Presentation (bo

Saturday, 1 February: Learning from heterogeneity to improve outcomes in PH

08:00-11:00	Session 5: The individual exposome ar
11:00-12:45	Buffet lunch Windsor Barra, Ground Fl
11:00-12:00	Hot topics from PVRI GoDeep (bookat
12:00-12:45	Pulmonary Circulation Meeting (closed
12:45-13:45	Session 6: Quantifying therapeutic res
13:45-14:15	Refreshment break
14:15-16:15	Session 7: Leveraging disease heterog



ve (IDDI) Meeting, Oceania IX ase (iPVD) Consortium Meeting, Oceania X e Task Force Meeting, Oceania II for Genetic Studies in PAH Meeting, Oceania II Ш eania X

for the classification and diagnosis of PH worldwide Floor, Barra Restaurant), Windsor Barra, 2nd Floor, Alhambra & El Pardo ment in the new era of PH therapeutics

all), Windsor Barra, 2nd Floor, Alhambra & El Pardo

chronic lung disease loor, Barra Restaurant Nindsor Barra, 2nd Floor, Alhambra & El Pardo iated with heart disease

ookable), Windsor Barra, Ground Floor, Louvre

and its contribution to PH heterogeneity Floor, Barra Restaurant able), Windsor Oceanico, 3rd Floor, Asia ed), Windsor Oceanico, 2nd Floor, Oceania VIII sponses

geneity in clinical trial design



Innovative Drug Development Initiative (IDDI)

Session 1: Introduction

08:00-08:05	Welcome Speaker TBC		
08:05-08:20	PVRI IDDI Introduction and organisational changes Luke Howard, Peter Fernandes, Sandeep Sahay & Sylvia Nikkho		
	ew Modalities & Technologies in RHF & PH Fernandes, Luke Howard		
08:20-09:00	Update on recent advances with inhalation of drugs in PH, emphasis on PAH & PH-ILD Speaker TBC		
09:00-09:40	Recent advances in diagnosis & treatment of PH and RHF, & the potential of in silico studies using GoDeep Speaker TBC		
09:40-10:20	Advancements in the use of Digital Health Technology from regulatory, pharma & academic stakeholders: "Articulating the clinical, economic, and patient- centric value of digital endpoints" Speaker TBC		
10:20-10:40	Refreshment break		
Session 3: Real World Evidence / Real World Data Co-Chairs: Kellie Morland, Jason Weatherald			
10:40-10:50	Real World Data Delphi to establish core data for global PH Registries Sandeep Sahay		
10:50-11:05	Sarah Cohen		
11:05-11:15	Group discussion		
Session 4: Patient Engagement & Empowerment			
11:15-11:35	Understanding the patient perspective to advance care Matt Granato		
Session 5: Access to Care			
11:35-11:55	Access to Care Workstream achievement and plan Vijay Balasubramanian, Sandeep Sahay		
11:55-12:05	Group discussion		

Presentation on the Workstream paper "Clinical trial 12:05-12:15 design, end-points, and emerging therapies in PAH", (Weatherald 2024, ERJ) & the key discussions that led to its development Jason Weatherald 12:15-12:22 Clinical trial endpoints Harm Jan Bogaard 12:22-12:30 Insights on clinical trial design from the perspective of industry CQ Deng 12:30-12:35 Group discussion 12:35-13:35 Lunch break **Session 7: Lung Transplantation in PH** Chair: Reda Girgis 13:35-13:50 Anaesthetic Management of PAH Andrea Miltiades 13:50-14:05 VA ECMO in PAH Lara Schaheen 14:05-14:15 Group discussion **Session 8: Paediatric Clinical Trial Design & Endpoints** Co-Chairs: Steve Abman, Sylvia Nikkho Theme: Heterogeneity in Paediatric PH 14:15-14:25 Introduction Steven Abman 14:25-14:35 adult data Sylvia Nikkho - remote 14:35-14:45 Challenges of drug development in bronchopulmonary dysplasia Steven Abman & Bernard Thebaud- remote 14:45-14:55 Group discussion Session 9: PH Group III Co-Chairs: Steve Nathan, Sylvia Nikkho 14:55-15:05 Past, present, & future of PVD in COPD Gabor Kovacs 15:05-15:15 Imaging in PH and chronic lung disease Shelsey Johnson 15:15-15:25 Group discussion 15:25-16:00 Wrap up and final comments

& Endpoints

Co-Chairs: Harm Jan Bogaard, CQ Deng

Session 6: Challenges of Clinical Trial Design, Conduct

Wednesday **29 January** Windsor Oceanico, 2nd Floor, Oceania IX

Enhancement of drug development in paediatric PAH – extrapolation from available



Infection in Pulmonary Vascular Disease (iPVD) Consortium Task Force

08:00-08:05	Welcome and opening remarks Navneet Dhillon
Session 1: Current updates on infection associated PVDs Chairs: Navneet Dhillon, Suellen Oliveira	
08:05-08:25	Pulmonary vascular complications of tuberculosis: PH and beyond Brian Allwood
08:25-08:45	Update on multiple co-morbidities and PVD Peter Nyasulu
08:45-09:05	Update on HIV and PVD Ana Olga Mocumbi
09:05-09:25	Mechanistic overlap between inflammatory pathways relevant to PH and COVID-19 Stephen Chan
09:25-09:45	Pathobiology of inflammatory immune cells in schistosoma induced PH Rahul Kumar
09:45-10:05	Fungal infections induced PH Alexandre Fabro
10:05-10:30	Refreshment break
Session 2: Schistosomiasis associated PVD in Latin America Chairs: Ghazwan Butrous, Brian Graham	
10:30-10:50	Overview of Sch-PAH: case-based presentation of the disease spectrum Angela Bandeira
10:50-11:10	Clinical and epidemiological aspects of Sch-PAH in Bahia Camila Loureiro
11:10-11:30	Clinical and epidemiological aspects of Sch-PAH in Minas Gerais Ricardo Correa

	11:30-11:50	Clinical presentation of hepatoesplenic schistosomiasis in Brazil Roberto José Carvalho
	11:50-12:10	Advances in schistosomiasis basic resear Katia Oliveira
	12:10-12:30	Insights from NIH schistosomiasis PAH m Rudolf Oliveira
	12:30-13:30	Lunch break
		ssions on schistosomiasis beet K Dhillon, Suellen Oliveira
	13:30-14:00	Panel 1: Current challenges in diagnosing availability and diagnostic tools Chair: Rogerio Souza Panel: Eliane Mancuzo, Camila Rezende,
	14:00-14:30	Panel 2: Epidemiological and preventive current status, future perspectives, and i Chair: Ricardo Correa Panel: Miriam Tendler, Roberto José Carv
_	14:30-15:00	Refreshment break
_		econd hit phenomenon in infection asso olf Oliviera, Vinicio de Jesus Perez
	15:00-15:20	Air pollution, climate change, infection ar Mona Lichtblau
	15:20-15:40	Emerging insights into HIV- and metham to management Prangthip Charoenpong
	15:40-16:00	Microbiome and schistosomiasis Suellen Oliveira



Wednesday 29 January

Windsor Oceanico, 2nd Floor, Oceania X

search: insights from Brazil

H multicenter study

sing schistosomiasis, including biomarker

de, Camila Loureiro

ive aspects of schistosomiasis in Brazil, including nd impact on PH development

Carvalho, Rudolf Oliveira, Angela Bandeira

ssociated PVDs

n and PH

amphetamine-driven PAH: From mechanisms

Paediatric & Congenital Heart Disease Task Force

-			
	Opportunities for involvement with the Paediatric Task Force		
)	08:00-08:03	Introduction and overview. Future directions for the Paediatric Task Force Maria Jesus del Cerro	
, 1 1	Ongoing activities and new opportunities at PVRI Chair: Maria Jesus del Cerro		
)	08:03-08:15	PVRI Pulmonary Hypertension Global Patient Survey (PH GPS) Shahin Moledina	
, 	08:15-08:23	PVRI Innovative Drug Development Initiative (IDDI) Steven Abman	
)	08:23-08:30	PVRI GoDeep Registry Megan Griffiths	
	08:30-08:40	Discussion All	
		n among international registries in Modelina, Rolf Berger	
	08:40-08:55	Collaboration between registries: Let's make it real Mary Mullen, Shahin Moledina, Maria del cerro, Rolf Berger	
	08:55-09:10	What adaptations are needed? Do we need rules? Maria Jesus del Cerro, Megan Griffiths	
	09:10-09:40	Discussion All	
	l have a rese	arch project I want to share	
	09:40-09:50	Genetics of PH study Eric Austin	
	09:50-10:00	Ongoing research: Genetic variants in pediatric PH across different registries & countries Rolf Berger	
	10:00-10:10	Ongoing research: Boston Children's Hospital Mary Mullen	
	10:10-10:20	Ongoing research in PAH in complex congenital heart disease in Mexico Humberto Garcia-Aguilar	
	10:20-10:35	Refreshment break	

7th World Symposium summary Chairs: Rolf Berger, Mary Mullen

10:35-10:45	Major recommendations & rationale Dunbar Ivy
10:45-10:50	Neonatal PH: Disease phenotypes & Steven Abman
10:50-11:30	Discussion All

I have a clinical case I want to discuss Chair: Usha Krishnan

11:30-12:00 2 Cases to be presented



Wednesday 29 January

Windsor Oceanico, 2nd Floor, Oceania II

next steps

Imaging Task Force

International imaging datasets, analysis methods & clinical impact 13:30-13:40 Introduction David Kiely Session 1: International PH imaging data Chair: Khodr Tello, David Kiely (TBC) 13:40-13:55 PVRI Imaging Task Force: updates and future endeavours David Kiely, Andy Swift, Rebecca Vanderpool 13:55-14:10 Integration of imaging into the GoDeep registry: challenges and opportunities Khodr Tello 14:10-14:25 Imaging practice in PH experience in South America Rogerio Souza, Flavia Navarro (TBC) 14:25-14:50 Open discussion on integration of imaging into PVRI GoDeep All > Summary of the session > Focused discussion on integration of data and opportunities > What data to integrate > How to collect, anonymise and store data > Database access and management > Opportunities for large scale analysis and large outcome studies 14:50-15:10 Refreshment break

Session 2: Current & novel imaging approaches to improve diagnosis & phenotyping Chairs: Raul San Jose Estepar, Sandeep Sahay (TBC)

15:10-15:25	CT Imaging approaches for phenotyping of patients with PH Lilian Meijboom
15:25-15:40	Developments in CT imaging for pulmonary vessels Farbod Rahaghi
15:40–16:00	4D Flow in PH: better insights into PH hemodynamics Mohammed Elbaz, Ben Freed
16:00-16:15	Questions & roundtable discussion All
16:15-16:30	Refreshment break

Session 3: Using microCT & computational/AI approaches to improve our understanding of PVD Chairs: David Kiely, Rebecca Vanderpool

16:30-16:45	Synchrotron-based phase-contrast m (micro-CT) in pulmonary vascular phe Karin Tran Lundmark
16:45-17:00	Emerging computational approaches Pietro Nardelli
17:00-17:15	Clinical applications of Al Andy Swift
17:15-17:30	Questions and roundtable discussion All
17:30-17:40	Closing remarks Rebecca Vanderpool, David Kiely



Wednesday **29 January**

Windsor Oceanico, 2nd Floor, Oceania III

microcomputed tomography enotypes

in imaging for PH



PAH-ICON: International Consortium for Genetic Studies in PAH

12:30-12:40	Welcome Micheala Aldred, Stefan Gräf	
Invited presentations & panel discussions Each talk includes 10 minutes of discussion time		
12:40-13:20	Keynote: Rare disease landscape in Brazil and Latin America Roberto Giugliani	
13:20-14:00	Update from ClinGen PAH gene and variant expert panel Carrie Welch	
14:00-14:40	Update from the TBX4Life initiative Eric Austin	
14:40-14:50	Refreshment break	
Abstract pre 14:50-15:10	sentations Late onset pulmonary veno-occlusive disease associated with rare heterozygous variants of KDR and EIF2AK4 Vasile Foris	
15:10-15:30	Functional characterization of novel KV1.5 variants in PAH Andrea Olschewski	
15:30-15:50	Spatial profiling identifies localised changes in gene expression in pulmonary vascular remodeling in the sugen hypoxia rat model James Klinger	
15:50-16:10	Pathogenic PAH gene variants linked to pulmonary vascular pruning in non-hispanic white COPD gene participants Vasile Foris	
16:10-16:30	Smaller right ventricular volumes correlate with elevated afterload in unaffected carriers of a pathogenic BMPR2 variant Eszter Tóth	
16.20 16.15	Pefreehment breek	

16:30-16:45 Refreshment break

Building future PH cohorts

16:45-18:00

- > Examples and experiences from around the globe
- > PVRI GoDeep's future perspective
- > Core data set: Standardisation & harmonisation of phenotypes
- > Leveraging image data
- > Resources, federation & analysis strategies
- > Global ethics & governance

High-Altitude Task Force

Challenges to the pulmonary circulation & beyond at high altitude

Moderators: Aastha Mishra, Silvia Ulrich		
Each talk includes 10 minutes of discussion time		
16:00-16:30	Birth at high altitude – immediate ch Alexandra Heath	
16:30-17:00	The role of the endothelium in acute to hypoxia Wolfgang Kübler	
17:00-17:30	Patients diagnosed with pulmonary Silvia Ulrich	
17:30-18:00	Lowlanders with COPD going to altit pulmonary vasculature Mona Lichtblau	
18:00-18:30	High Altitude Task Force meeting	



Wednesday 29 January Windsor Oceanico, 2nd Floor, Oceania X

allenges & life-long consequences

e & chronic pulmonary vascular adaptation

vascular disease (PAH/CTEPH) at high altitude

tude – implication for the right heart & the

Scientific programme speakers



Steven Abman University of Colorado

Stephen Chan

School of Medicine

Anna Hemnes

Medical Center

Vanderbilt University

Maria Jesus del

Hospital Universitario

Cerro Marin

University of Pittsburgh



Prashant Bobhate Kokilaben Dhirubai Ambani Hospital





Vinicio de Jesus

Stanford University

Rachel Hopper

Lucile Packard

David Kiely

Grazyna

Health

University of Sheffield

Kwapiszewska

Medical University

Allan Lawrie

London

Center

Imperial College

Graz & Institute of Lung

Perez

Vineet Agrawal

Medical Center

Vanderbilt University

Evan Brittain Vanderbilt University Medical Center

Rolf Berger

University Medical

Center Groningen



Kara Goss UT Southwestern Medical Center



Dunbar Ivy Children's Hospital Colorado/University of Colorado School of Medicine



Gabor Kovacs Medical University of Graz

Tim Lahm



National Jewish Health - University Of





Valentina Mercurio Federio II University

Rudolf Oliveira Federal University of Sao Paulo

Ioana Preston Lahey Clinic



Catherine Simpson Johns Hopkins University

Natascha Sommer University of Giessen & Marburg Lung Center

Spiekerkoetter Stanford University

Charlotte **Summers**



Caio Tavares Imperial College London

Karin Tran-

Lundmark

University

Rebecca

University

Vanderpool

The Ohio State

Brown University

Martin Wilkins

Imperial College

London

Skane University

Hospital & Lund

Edda













Hospital 14 #PVRI2025



Charité -Universitätsmedizin Berlin



Charly Lai Indiana University School of Medicine



Bradley Maron University of Maryland

Shahin Moledina Great Ormond Street



Imperial College London



Hiromi Matsubara

Okayama Medical



National Jewish Health





Sasha Prisco University of Minnesota

Soni Savai-Pullamsetti Max Planck Institute



Farbod (Nick) Rahaghi Brigham and Women's Hospital / Harvard Medical School



Sandeep Sahay Houston Methodist Hospital



Rogerio Souza University of Sao Paulo Medical School



Andrew Swift University of Sheffield



Mark Toshner University of Cambridge



Silvia Ulrich University Hospital Zurich



Frances Varian University of Sheffield



Jason Weatherald



University of Alberta

Nayeli Zayas Instituto Nacional de Cardiologia Ignacio Chavez

University of Cambridge

Khodr Tello University Hospital Giessen

Rubin Tuder University of Colorado Anschutz Medical Campus

Nidhy Varghese Texas Children's Hospital

Sofia Villar University of Cambridge

Roham Zamanian Stanford University

SESSION 1: Establishing the framework for the classification & diagnosis of PH
worldwide

	Moderators: Katarina Zeder, Lindsay Forbes, Sonja Bartolome			Moderators: F	Pilar Escribano Subias, Sue Gue, Sandee	
	08:00-08:05	PVRI President's welcome				
5		Anna Hemnes		13:00-13:15	Developments in risk stratification scor Valentina Mercurio	
	08:05-08:20	PH care in Brazil				
		Rogerio Souza		13:15-13:30	RV phenotyping in PH risk stratification Tim Lahm	
	08:20-08:35	Classification & diagnosis of PH: Updates from the 7th WSPH				
		Gabor Kovacs		13:30-13:45	The impact of novel therapeutics on the Sandeep Sahay	
	08:35-08:50	Omics-based & data-driven approaches to early disease diagnosis				
		Catherine Simpson		13:45-13:52	A monoclonal antibody targeting the Z experimental PAH	
	08:50-08:57	The prevalence of PH in sickle cell disease in sub-Saharan Africa: A systematic review & meta-analysis			Stephanie Hopley	
		Armella Santi		13:52-14:07	Surgical Interventions, mechanical sup Nayeli Zayas	
	08:57-09:12	CIPHER & CIPHER-MRI studies for early diagnosis of PH				
		Ioana Preston	_	14:07-14:37	Refreshment break	
)	09:12-09:27	Advanced medical imaging & AI in PH diagnosis & classification Andy Swift		Moderators: C	Corey Ventetuolo, Athiththan Yogeswara	
		•		14:37-14:52	Approach to the treatment of Group 1	
	09:27-09:57	Refreshment break			Anna Hemnes	
		atiana Kudryashova, Tim Lahm, Gabor Kovacs		14:52-15:07	Risk stratification & treatment of paedia	
	09:57-10:12	Cardiopulmonary exercise testing in the diagnosis & phenotyping of PH patients			Rolf Berger	
		Khodr Tello		15:07-15:15	Preclinical models support the synergi treating PAH	
	10:12-10:27	Classification & diagnosis of paediatric PH: Updates from the 7th WSPH Dunbar Ivy			Daniel Bachteler	
				15:15-15:30	Medical & surgical management of CT	
	10:27-10:35	Global treatment disparities within high- and middle-high income PH centers: A cluster analysis by the PVRI IDDI Access to Care Workstream			Hiromi Matsubara	
		Franz Rischard		15:30-16:00	Panel discussion: Realities & challenge treatment in LMIC	
	10:35-10:50	CTEPH & CTED approach to early diagnosis & treatment Mark Toshner			Facilitators: Vinicio de Jesus Perez, We Mauricio Orozco Levi	
	10:50-11:05	How pre-clinical models can be used to improve clinical phenotyping &		16:00-18:00	Poster presentations	
		early diagnosis Vineet Agrawal		18:00-19:30	Drinks Reception, Windsor Barra, 2nd F	
	11:05-13:00 11:05-13:00	Lunch break, Windsor Barra, Ground Floor, Barra Restaurant Career Catalyst Luncheon, Windsor Barra, 2nd Floor, Alhambra & El Pardo Hosts: Jason Weatherald, Laura Oppegard, Katarina Zeder and Navneet Singh				

SESSION 2: Risk stratification & treatment in the new era

eep Sahay

of PH therapeutics

cores in PH

ion & treatment

the treatment algorithm of PH

ZIP12 transporter attenuates severe

Thursday

30 January

Windsor Oceanico, <u>3r</u>d Floor , Asia

support, & transplant in end-stage PH

ran, Horst Olschewski

1 PH patients with co-morbidities

diatric PH

rgistic potential of seralutinib & sotatercept in

CTED & CTEPH

ges of applying PH guidelines for diagnosis &

Werner Seeger, Ana Mocumbi, Gerald Maarman,

d Floor, Alhambra & El Pardo



	SESSION 3: Vascular heterogeneity in chronic lung disease				
		arazyna Kwapiszewska, Shelsey Johnson, Susan Majka			
	08:00-08:05	Introduction Grazyna Kwapiszewska			
	08:05-08:20	Clinical aspects of PH heterogeneity in chronic lung disease: Same as PAH or different? Corey Ventetuolo			
	08:20-08:35	Translational investigations of PH in fibrotic lung disease models Susan Majka			
	08:35-08:42	RUPERT SWIFT AWARD LECTURE: Cluster analysis identifies computed tomography imaging-based phenotypes of PH associated with COPD-PH Shelsey Johnson			
	08:42-08:50	Endotyping PH in COPD: possible role of systemic & lung iron status Horst Olschewski			
	08:50-09:05	Translational investigations of PH in COPD disease models Natascha Sommer			
	09:05-09:20	Panel discussion: Comparison of vascular changes in CLD & PAH			
-	09:20-09:50	Refreshment break			
	Moderators:	David Kiely, Mona Lichtblau, Sarah MacIssac			
	09:50-09:55	Introduction David Kiely			
	09:55-10:10	Vasculature in CLD: Imaging insights Farbod (Nick) Rahaghi			
	10:10-10:25	Pulmonary vascular heterogeneity: Insights from contemporary pathological approaches Rubin Tuder			
	10:25-10:33	Elevated vascular hyaluronan as a therapeutic target in PH associated with lung fibrosis Harry Karmouty Quintana			
	10:33-10:40	BUTROUS FOUNDATION YOUNG INVESTIGATOR AWARD LECTURE: Impact of IRG1/Itaconate axis on cardiopulmonary phenotype: linking bone marrow dynamics to inter-organ communication Golnaz Hesami			
	10:40-10:55	Vascular changes in paediatric chronic lung disease Steven Abman			
	10:55-11:10	Panel discussion: Should we target vascular changes in chronic lung disease?			
	11:10-13:00	Lunch break, Windsor Barra, Ground Floor, Barra Restaurant			
	11:10-13:00	Women in PH Luncheon, Windsor Barra, 2nd Floor, Alhambra & El Pardo Host: Anna Hemnes Speakers: Jill Maron, Karin Tran-Lundmark, Ana Olga Mocumbi			

SESSION 4: Heterogeneity in PH associated with heart disease

Moderators: N	lidhy Varghese, Baktybek Kojonazarov, I
13:00-13:05	Introduction Nidhy Varghese
13:05-13:20	How do HFrEF & HFpEF affect the pull Charly Lai
13:20-13:35	Congenital heart disease & the pulmo Shahin Moledina
13:35-13:42	PH is highly prevalent in rheumatic he review & meta-analysis Katarina Zeder
13:42-13:57	Animal models of heart disease PH Wolfgang Kübler
13:57-14:05	17β-Estradiol enhances right ventricle oxidation in PAH in a carnitine palmito Simon Bousseau
14:05-14:20	Effect of pre and post-tricuspid shunts Rachel Hopper
14:20-14:50	Refreshment break
Moderators:	Harm Jan Bogaard, Evan Brittain, Phili
14:50-14:55	Introduction Harm Jan Bogaard
14:55-15:10	How can we study the right ventricle t Edda Spiekerkoetter
15:10-15:17	The role of SMYD2/RUNX2 axis in righ Vandna Sapehia
15:17-15:32	Advances in imaging RV function in hu Rebecca Vanderpool
15:32-15:40	Effects of Dapagliflozin on PH in a rat p Leonhard Blumrich
15:40-15:55	Cellular heterogeneity in RV dysfuncti Soni Savai-Pullamsetti
15:55-16:10	Managing RV dysfunction in resource Prashant Bobhate
16:10-16:30	Panel discussion
16:30-18:00	Poster presentations
19:00-23:59	Gala Dinner & Award Presentations, V

Rebecca Vanderpool

Friday **31 January** Windsor Oceanico, 3rd Floor, Asia

Imonary vasculature & how can we model it?

onary vasculature

eart disease in sub-Saharan Africa: a systematic

e angiogenesis & endothelial cell fatty acid oyltransferase 1-dependent manner

its on the pulmonary vasculature

ilipp Douschan

to develop novel therapies?

ht ventricular hypertrophy & failure

numans & animal models with PH

pulmonary vein banding (PVB) model

tion

e-limited settings

Windsor Barra, Ground Floor, Louvre



SESSION 5:	The individual exposome & its contribution to PH heterogeneity	SESSION 6: 0	Quantifying therapeutic responses
Moderators: L	an Zhao, Navneet Dhillon, Harry Karmouty Quintana	Moderators:	Patricia Thistlethwaite, Andy Sweatt, Steeve Provencher
08:00-08:15	Drug exposures and PH Vinicio de Jesus Perez	12:45-13:00	How should we define disease modification? Roham Zamanian
08:15-08:30	Infectious exposures & pulmonary vascular disease Rudolf Oliveira	13:00-13:15	Developing imaging surrogates of vascular histology to qua Karin Tran-Lundmark
08:30-08:45	High altitude exposure and PH Silvia Ulrich	13:15-13:23	CT-based discrimination of CTEPH using deep learning clot machine learning Pietro Nardelli
08:45-09:00 09:00-09:15	Early life exposures and pulmonary vascular disease Kara Goss The Microbiome in PH Sasha Prisco	13:23-13:30	Novel insights from functional respiratory imaging (FRI) ana study: Treprostinil palmitil inhalation powder (TPIP) impact of patients with PH-ILD Colin Church
09:15-09:45	Refreshment break	13:30-13:45	A joint talk with PVRI and PHA USA
Moderators: I	Flavia Navarro, Luke Howard, Rudolf Oliveira		Patient reported outcomes Frances Varian
09:45-10:00	Less considered exposures that contribute to PH Stephen Chan	13:45-14:15	Refreshment break
10:00-10:07	Novel potential connection between lung microbiome dysbiosis & P2X7R/c-IAP2-regulated endothelial survival in schistosomiasis-associated PH Suellen Darc Oliveira	SESSION 7:	Leveraging disease heterogeneity in clinical trial des
10:07-10:22	Real world activity and exercise perception in PH patients - MyHeart Counts Allan Lawrie	Moderators:	Jane Leopold, Navneet Singh, Roham Zamanian
10:22-10:37	Insights from All of Us/EHR Evan Brittain	14:15-14:30	What is a platform trial? Charlotte Summers
10:37-10:45	Early recruitment & alternative activation of macrophages initiate pathophysiological changes in pulmonary vasculature upon smoke exposure	14:30-14:45	Global perspective & digital trials Caio Tavares
10:45-11:00	Vinita Sharma Exposome as a modifiable factor for PH management	14:45-15:00	Update in paediatric clinical trials Maria Jesus del Cerro
	Bradley Maron		n / Shark Tank rden Geneie Deutscheren Anderskie Oberferni, Oberlette Summeren V
11:00-12:45	Lunch break, Windsor Barra, Ground Floor, Barra Restaurant		rks: Sonja Bartolome, Ardeshir Ghofrani, Charlotte Summers, H
11:00-12:00	Hot topics from PVRI GoDeep Chairs: Martin Wilkins, Paul Hassoun, Werner Seeger	15:00-15:05 15:05-15:20	Dragon Den introduction Martin Wilkins PHoenix trial (rationalising current treatments using implant
	Overview of the GoDeep meta-registry Werner Seeger	15:20-15:35	Stratosphere Baysian trial for BMPR2 mutation carriers Sofia
	 Risk scores beyond group 1 PH – baseline and follow-up Athiththan Yogeswaran Survival outcomes and Impact of targeted PAH therapy in PoPH Arun Jose 	15:35-15:50	CRAVE: Canadian Right ventricular AdaptiVE platform trial J

15:50-16:00

16:00-16:15

Summary Martin Wilkins

Steve Niederer

- Survival outcomes and Impact of targeted PAH therapy in PoPH Arun Jose •
- PAH-targeted therapies in group 3 PH PDE5 inhibitor therapy associated • with improved survival Khodr Tello
- Male survival disadvantage in PH: independent of etiology, age, disease • severity, comorbidities and treatment, but race-dependent Evan Brittain



Saturday **1** February Windsor Oceanico, 3rd Floor, Asia

uantify reverse remodeling

lot vessel radiomics &

nalysis in phase 2 INS1009-211 t on pulmonary vasculature in



esign

Paul Corris

nted devices) Alex Rothman

fia Villar

15:35-15:50 CRAVE: Canadian Right ventricular AdaptiVE platform trial Jason Weatherald

Building and testing a personal digital twin for PH

